Artificial intelligence has many clinical and non-clinical use cases within the drug development lifecycle, but mitigating risks will require a culture where individuals “are not afraid to say that they are wrong,” says a senior EU regulator.
The European Medicines Agency is currently mulling how best to regulate the use of artificial intelligence in the medicines development lifecycle, and this week invited hundreds of pharma industry stakeholders to participate in a two-day workshop on the subject, held jointly with the EU Heads of Medicines Agencies (HMA)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?